Sign in or create an account to add this stock to your watchlist.
About Dicerna Pharmaceuticals (NASDAQ:DRNA)
Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infectious, chronic liver, and cardiovascular diseases. Its development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. The company has a collaborative research and license agreement with Boehringer Ingelheim International GmbH; a research collaboration and license agreement with Kyowa Hakko Kirin Co., Ltd.; and a license agreement with City of Hope. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Trailing P/E Ratio-3.77
Forward P/E Ratio-10.67
Sales & Book Value
Annual Sales$2.28 million
Price / Sales319.01
Price / CashN/A
Book Value$1.66 per share
Price / Book8.30
EPS (Most Recent Fiscal Year)($3.66)
Return on Equity-123.72%
Return on Assets-61.06%
Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions
What is Dicerna Pharmaceuticals' stock symbol?
Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."
How were Dicerna Pharmaceuticals' earnings last quarter?
Dicerna Pharmaceuticals (NASDAQ:DRNA) released its quarterly earnings results on Monday, May, 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.87) by $0.57. The biopharmaceutical company earned $1.55 million during the quarter, compared to analysts' expectations of $1.75 million. Dicerna Pharmaceuticals had a negative net margin of 1,665.11% and a negative return on equity of 123.72%. View Dicerna Pharmaceuticals' Earnings History.
When is Dicerna Pharmaceuticals' next earnings date?
What price target have analysts set for DRNA?
7 analysts have issued 12-month price objectives for Dicerna Pharmaceuticals' shares. Their forecasts range from $10.00 to $17.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $14.20 in the next twelve months. View Analyst Ratings for Dicerna Pharmaceuticals.
Who are some of Dicerna Pharmaceuticals' key competitors?
Some companies that are related to Dicerna Pharmaceuticals include Amicus Therapeutics (FOLD), Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), TESARO (TSRO), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Emergent Biosolutions (EBS), Clovis Oncology (CLVS), Horizon Pharma (HZNP), Evotec A.G. (EVTCY), Global Blood Therapeutics (GBT), The Medicines (MDCO), Arena Pharmaceuticals (ARNA), Heron Therapeutics (HRTX) and ACADIA Pharmaceuticals (ACAD).
Who are Dicerna Pharmaceuticals' key executives?
Dicerna Pharmaceuticals' management team includes the folowing people:
- Dr. Douglas M. Fambrough III, Ph.D., Co-Founder, Chief Exec. Officer, Pres and Director (Age 49)
- Mr. John B. Green CPA, Chief Financial Officer (Age 64)
- Dr. Bob D. Brown Ph.D., Chief Scientific Officer and Sr. VP (Age 53)
- Dr. Mark Behlke M.D., Ph.D., Co-Founder and Member of Scientific Advisory Board
- Prof. John J. Rossi Ph.D., Co-Founder and Chairman of Scientific Advisory Board (Age 71)
Has Dicerna Pharmaceuticals been receiving favorable news coverage?
Press coverage about DRNA stock has been trending somewhat positive this week, according to Accern. The research group ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a news impact score of 0.15 on Accern's scale. They also gave news stories about the biopharmaceutical company an impact score of 46.47 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
Who are Dicerna Pharmaceuticals' major shareholders?
Dicerna Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include UBS Group AG (1.16%), Artal Group S.A. (0.82%), Millennium Management LLC (0.79%), BlackRock Inc. (0.54%), Citadel Advisors LLC (0.33%) and Spark Investment Management LLC (0.28%). Company insiders that own Dicerna Pharmaceuticals stock include Bain Capital Life Sciences Inv, Dennis Langer, Douglas Fambrough and James B Weissman. View Institutional Ownership Trends for Dicerna Pharmaceuticals.
Which institutional investors are selling Dicerna Pharmaceuticals stock?
Which institutional investors are buying Dicerna Pharmaceuticals stock?
DRNA stock was acquired by a variety of institutional investors in the last quarter, including Artal Group S.A., Millennium Management LLC, Citadel Advisors LLC, BlackRock Inc., Spark Investment Management LLC, JPMorgan Chase & Co., Element Capital Management LLC and Tibra Equities Europe Ltd. Company insiders that have bought Dicerna Pharmaceuticals stock in the last two years include Bain Capital Life Sciences Inv and Douglas Fambrough. View Insider Buying and Selling for Dicerna Pharmaceuticals.
How do I buy shares of Dicerna Pharmaceuticals?
Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Dicerna Pharmaceuticals' stock price today?
One share of DRNA stock can currently be purchased for approximately $13.77.
How big of a company is Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals has a market capitalization of $725.24 million and generates $2.28 million in revenue each year. The biopharmaceutical company earns $-60,040,000.00 in net income (profit) each year or ($3.66) on an earnings per share basis. Dicerna Pharmaceuticals employs 44 workers across the globe.
How can I contact Dicerna Pharmaceuticals?
Dicerna Pharmaceuticals' mailing address is 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA, 02140. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]
MarketBeat Community Rating for Dicerna Pharmaceuticals (DRNA)MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote "Outperform" if you believe DRNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
Dicerna Pharmaceuticals (NASDAQ:DRNA) Price Target and Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
7 Wall Street analysts have issued ratings and price targets for Dicerna Pharmaceuticals in the last 12 months. Their average twelve-month price target is $14.20, suggesting that the stock has a possible upside of 3.12%. The high price target for DRNA is $17.00 and the low price target for DRNA is $10.00. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||2.57||2.57||2.83||2.60|
|Ratings Breakdown: ||0 Sell Rating(s)|
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
|0 Sell Rating(s)|
2 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
|Consensus Price Target: ||$14.20||$13.80||$11.00||$7.00|
|Price Target Upside: ||3.12% upside||14.62% upside||21.01% upside||3.18% downside|
Dicerna Pharmaceuticals (NASDAQ:DRNA) Consensus Price Target History
Dicerna Pharmaceuticals (NASDAQ:DRNA) Analyst Ratings History
(Data available from 5/25/2016 forward)
Dicerna Pharmaceuticals (NASDAQ:DRNA) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Dicerna Pharmaceuticals (NASDAQ DRNA) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 19.85%
Institutional Ownership Percentage: 77.75%
Dicerna Pharmaceuticals (NASDAQ DRNA) Insider Trading History
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|5/9/2018||James B Weissman||Insider||Sell||10,000||$15.00||$150,000.00||19,800|| |
|4/20/2018||James B Weissman||Insider||Sell||8,965||$13.00||$116,545.00||9,800|| |
|3/19/2018||James B Weissman||Insider||Sell||1,035||$13.00||$13,455.00||18,765|| |
|12/18/2017||Bain Capital Life Sciences Inv||Director||Buy||285,000||$7.00||$1,995,000.00|| |
|11/16/2016||Dennis Langer||Director||Sell||23,766||$3.52||$83,656.32||43,595|| |
|11/15/2016||Douglas Fambrough||CEO||Buy||33,100||$3.71||$122,801.00|| |
|5/12/2016||James B Weissman||Insider||Buy||5,000||$3.29||$16,450.00||15,100|| |
|11/25/2014||James E Flynn||Insider||Sell||321,965||$11.36||$3,657,522.40|| |
|11/7/2014||James E Flynn||Insider||Sell||214,164||$9.05||$1,938,184.20|| |
|10/15/2014||James E Flynn||Insider||Sell||117,778||$10.86||$1,279,069.08|| |
|10/14/2014||James E Flynn||Major Shareholder||Sell||36,115||$11.02||$397,987.30|| |
|10/10/2014||James E Flynn||Major Shareholder||Sell||30,214||$12.13||$366,495.82|| |
|2/4/2014||James E Flynn||Insider||Buy||1,000,000||$15.00||$15,000,000.00|| |
|2/4/2014||Stephen J Hoffman||Director||Buy||200,000||$15.00||$3,000,000.00|| |
Dicerna Pharmaceuticals (NASDAQ DRNA) News Headlines
|Dicerna Pharmaceuticals (DRNA) Expected to Post Quarterly Sales of $1.79 Million|
www.americanbankingnews.com - May 22 at 2:16 AM
|Zacks: Analysts Anticipate Dicerna Pharmaceuticals (DRNA) to Post -$0.46 Earnings Per Share|
www.americanbankingnews.com - May 20 at 9:06 PM
|Research Report Identifies Carolina Financial, Dicerna Pharmaceuticals, On Assignment, Digimarc, CIRCOR International, and Nordson with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement|
finance.yahoo.com - May 18 at 9:22 AM
|Brokers Issue Forecasts for Dicerna Pharmaceuticals' Q2 2018 Earnings (DRNA)|
www.americanbankingnews.com - May 18 at 7:38 AM
|Dicerna Pharmaceuticals (DRNA) Given Consensus Recommendation of "Buy" by Brokerages|
www.americanbankingnews.com - May 17 at 6:11 PM
|FY2018 EPS Estimates for Dicerna Pharmaceuticals (DRNA) Reduced by B. Riley|
www.americanbankingnews.com - May 17 at 7:14 AM
|BRIEF-Dicerna Pharmaceuticals Q1 Loss Per Share $0.30|
www.reuters.com - May 16 at 5:07 PM
|HC Wainwright Reaffirms Hold Rating for Dicerna Pharmaceuticals (DRNA)|
www.americanbankingnews.com - May 15 at 1:31 PM
|Dicerna Pharmaceuticals' (DRNA) CEO Douglas Fambrough on Q1 2018 Results - Earnings Call Transcript|
seekingalpha.com - May 15 at 9:06 AM
|Edited Transcript of DRNA earnings conference call or presentation 14-May-18 8:30pm GMT|
finance.yahoo.com - May 15 at 9:06 AM
|Dicerna Pharmaceuticals (DRNA) Posts Earnings Results, Beats Estimates By $0.57 EPS|
www.americanbankingnews.com - May 15 at 8:28 AM
|Dicerna Pharmaceuticals: 1Q Earnings Snapshot|
finance.yahoo.com - May 14 at 5:01 PM
|James B. Weissman Sells 10,000 Shares of Dicerna Pharmaceuticals (DRNA) Stock|
www.americanbankingnews.com - May 11 at 10:27 PM
|Despite Recurrent Market Jitters, Alnylam Is Closing In On Multiple Drug Approvals|
seekingalpha.com - May 7 at 8:45 AM
|Dicerna to Report First Quarter 2018 Financial Results and Host Conference Call on May 14, 2018|
finance.yahoo.com - May 7 at 8:45 AM
|Dicerna Pharmaceuticals (DRNA) Expected to Post Quarterly Sales of $1.75 Million|
www.americanbankingnews.com - May 5 at 3:54 AM
|Dicerna Pharmaceuticals (DRNA) Raised to Buy at BidaskClub|
www.americanbankingnews.com - May 5 at 12:29 AM
|-$0.30 Earnings Per Share Expected for Dicerna Pharmaceuticals (DRNA) This Quarter|
www.americanbankingnews.com - May 3 at 6:05 PM
|Dicerna Pharmaceuticals (DRNA) Upgraded at ValuEngine|
www.americanbankingnews.com - May 2 at 11:33 PM
|Dicerna Pharmaceuticals (DRNA) Set to Announce Earnings on Monday|
www.americanbankingnews.com - April 30 at 9:21 AM
|Dicerna Pharmaceuticals (DRNA) Insider Sells $116,545.00 in Stock|
www.americanbankingnews.com - April 24 at 10:22 PM
|Cowen Reiterates Buy Rating for Dicerna Pharmaceuticals (DRNA)|
www.americanbankingnews.com - April 24 at 9:06 PM
|Traders Purchase High Volume of Call Options on Dicerna Pharmaceuticals (DRNA)|
www.americanbankingnews.com - April 24 at 6:12 AM
|Health Care Sector Update for 04/23/2018: DRNA,ALNY,HSIC,BHVN,AKRX,FMS|
www.nasdaq.com - April 23 at 4:54 PM
|Does Dicerna's Settlement Agreement With Alnylam Make It A Buy?|
seekingalpha.com - April 23 at 8:36 AM
|Dicerna Pharmaceuticals (DRNA) Receives Consensus Rating of "Hold" from Analysts|
www.americanbankingnews.com - April 22 at 3:16 PM
|UPDATE: Dicerna Pharmaceuticals (DRNA) PT Raised to $17 at Evercore ISI Amid Settlement|
www.streetinsider.com - April 21 at 8:43 AM
|Evercore ISI Reiterates "Outperform" Rating for Dicerna Pharmaceuticals (DRNA)|
www.americanbankingnews.com - April 20 at 1:19 PM
|Zacks: Brokerages Expect Dicerna Pharmaceuticals (DRNA) Will Announce Earnings of -$0.30 Per Share|
www.americanbankingnews.com - April 16 at 9:25 AM
|ValuEngine Lowers Dicerna Pharmaceuticals (DRNA) to Sell|
www.americanbankingnews.com - April 14 at 2:31 PM
|Dicerna Pharmaceuticals (DRNA) Raised to "Buy" at ValuEngine|
www.americanbankingnews.com - April 12 at 11:18 AM
|Dicerna Pharmaceuticals (DRNA) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow|
seekingalpha.com - April 11 at 5:03 PM
|Dicerna to Present at the HC Wainwright Global Life Sciences Conference|
www.businesswire.com - April 3 at 8:56 AM
|Dicerna to Present at the H.C. Wainwright Global Life Sciences Conference|
finance.yahoo.com - April 3 at 8:56 AM
|Dicerna Pharmaceuticals (DRNA) Upgraded by ValuEngine to "Hold"|
www.americanbankingnews.com - April 1 at 10:20 PM
| Brokerages Anticipate Dicerna Pharmaceuticals Inc (DRNA) Will Post Quarterly Sales of $1.75 Million|
www.americanbankingnews.com - April 1 at 4:04 AM
|Dicerna Pharmaceuticals (DRNA) Lifted to Hold at ValuEngine|
www.americanbankingnews.com - March 31 at 2:40 PM
|Dicerna Pharmaceuticals (DRNA) Lowered to "Hold" at BidaskClub|
www.americanbankingnews.com - March 30 at 9:27 AM
|Equities Analysts Issue Forecasts for Dicerna Pharmaceuticals Inc's FY2018 Earnings (DRNA)|
www.americanbankingnews.com - March 30 at 7:05 AM
|Dicerna Pharmaceuticals Inc (DRNA) Receives Average Rating of "Hold" from Analysts|
www.americanbankingnews.com - March 28 at 5:56 PM
|Dicerna Pharmaceuticals (DRNA) Coverage Initiated by Analysts at Evercore ISI|
www.americanbankingnews.com - March 28 at 2:06 PM
|Dicerna Pharmaceuticals (DRNA) Downgraded by BidaskClub to Hold|
www.americanbankingnews.com - March 28 at 11:26 AM
|B. Riley Initiates Coverage on Dicerna Pharmaceuticals (DRNA)|
www.americanbankingnews.com - March 28 at 8:06 AM
|Dicerna Pharmaceuticals (DRNA) Stock Rating Upgraded by ValuEngine|
www.americanbankingnews.com - March 25 at 6:58 PM
|Dicerna Pharmaceuticals (DRNA) Lifted to "Strong-Buy" at BidaskClub|
www.americanbankingnews.com - March 24 at 8:23 PM
|H.C. Wainwright Downgrades Dicerna Pharmaceuticals (DRNA) to Neutral Citing Valuation|
www.streetinsider.com - March 24 at 4:55 PM
|Dicerna Pharmaceuticals (DRNA) Stock Rating Lowered by BidaskClub|
www.americanbankingnews.com - March 23 at 11:22 PM
|HC Wainwright Lowers Dicerna Pharmaceuticals (DRNA) to Neutral|
www.americanbankingnews.com - March 23 at 2:56 PM
|Report: Exploring Fundamental Drivers Behind Goldfield, Dicerna Pharmaceuticals, Deciphera Pharmaceuticals, WesBanco, Carolina Financial, and TriState Capital — New Horizons, Emerging Trends, and Upcoming Developments|
finance.yahoo.com - March 23 at 8:49 AM
|21 Stocks Moving In Thursday's Pre-Market Session - Benzinga|
www.benzinga.com - March 22 at 9:01 AM
Dicerna Pharmaceuticals (NASDAQ:DRNA) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Dicerna Pharmaceuticals (NASDAQ:DRNA) Income Statement, Balance Sheet and Cash Flow Statement
Dicerna Pharmaceuticals (NASDAQ DRNA) Stock Chart for Friday, May, 25, 2018